Switch theme
Sign up to access all valuation multiples
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. In addition, the group is also focused on the development of a treatment with a combination of a biodegradable medical device and a drug substance for complete spinal cord injury. Geographically, it derives a majority of its revenue from Asia.
2003
88
LTM Revenue $65.5M
LTM EBITDA $16.0M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioArctic has a last 12-month revenue of $65.5M and a last 12-month EBITDA of $16.0M.
In the most recent fiscal year, BioArctic achieved revenue of $25.6M and an EBITDA of -$18.6M.
BioArctic expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioArctic valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $61.2M | $25.6M | XXX | XXX | XXX |
| Gross Profit | $15.3M | $52.3M | XXX | XXX | XXX |
| Gross Margin | 25% | 205% | XXX | XXX | XXX |
| EBITDA | $29.3M | -$18.6M | XXX | XXX | XXX |
| EBITDA Margin | 48% | -73% | XXX | XXX | XXX |
| Net Profit | -$1.1M | $22.8M | XXX | XXX | XXX |
| Net Margin | -2% | 89% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, BioArctic's stock price is SEK 166 (or $16).
BioArctic has current market cap of SEK 14.7B (or $1.5B), and EV of SEK 14.2B (or $1.4B).
See BioArctic trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.5B | XXX | XXX | XXX | XXX | $0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, BioArctic has market cap of $1.5B and EV of $1.4B.
BioArctic's trades at 21.6x LTM EV/Revenue multiple, and 88.3x LTM EBITDA.
Analysts estimate BioArctic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for BioArctic and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 55.4x | XXX | XXX | XXX |
| EV/EBITDA | -75.9x | XXX | XXX | XXX |
| P/E | -83.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -45.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBioArctic's NTM/LTM revenue growth is 148%
BioArctic's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, BioArctic's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate BioArctic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for BioArctic and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -58% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -73% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -164% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 75% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 22% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 36% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 121% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 178% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioArctic acquired XXX companies to date.
Last acquisition by BioArctic was XXXXXXXX, XXXXX XXXXX XXXXXX . BioArctic acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was BioArctic founded? | BioArctic was founded in 2003. |
| Where is BioArctic headquartered? | BioArctic is headquartered in Sweden. |
| How many employees does BioArctic have? | As of today, BioArctic has 88 employees. |
| Who is the CEO of BioArctic? | BioArctic's CEO is Dr. Gunilla Osswald Osswald. |
| Is BioArctic publicy listed? | Yes, BioArctic is a public company listed on STO. |
| What is the stock symbol of BioArctic? | BioArctic trades under BIOA B ticker. |
| When did BioArctic go public? | BioArctic went public in 2017. |
| Who are competitors of BioArctic? | Similar companies to BioArctic include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BioArctic? | BioArctic's current market cap is $1.5B |
| What is the current revenue of BioArctic? | BioArctic's last 12-month revenue is $65.5M. |
| What is the current EBITDA of BioArctic? | BioArctic's last 12-month EBITDA is $16.0M. |
| What is the current EV/Revenue multiple of BioArctic? | Current revenue multiple of BioArctic is 21.6x. |
| What is the current EV/EBITDA multiple of BioArctic? | Current EBITDA multiple of BioArctic is 88.3x. |
| What is the current revenue growth of BioArctic? | BioArctic revenue growth between 2023 and 2024 was -58%. |
| Is BioArctic profitable? | Yes, BioArctic is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
